What question did this study set out to answer?

To evaluate the efficacy of plasma symmetric dimethylarginine as a biomarker for assessing kidney function in living donors.

March 28, 2026Open Access

Wcn26-6378 Plasma Symmetric Dimethylarginine as a Novel Biomarker of Kidney Function in Living Donors

Key Points

To evaluate the efficacy of plasma symmetric dimethylarginine as a biomarker for assessing kidney function in living donors.
Analysis of plasma symmetric dimethylarginine levels in living kidney donors.
Comparison with existing kidney function markers.
Evaluation of correlation with kidney function metrics.
Identification of significant associations between plasma dimethylarginine levels and kidney function.
Establishment of a novel biomarker profile for kidney function assessment.

Abstract

However, in the setting of low BKV and moderate CMV burden, this may limit the power to detect clinical significance.This abstract was previously presented at the Malaysian Society of Nephrology (MSN) meeting, and its re-submission is permitted by the original meeting organizers.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Weiwei Xu

Dion Groothof

Jiachuan Xiong

Journals

Kidney International Reports

Actions

Institutions

University of Groningen

University Medical Center Groningen

IDEXX Laboratories (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Wcn26-6378 Plasma Symmetric Dimethylarginine as a Novel Biomarker of Kidney Function in Living Donors

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study